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Objectives The goal of this study was to characterize the regulation of heme and non-heme iron in human failing hearts.
Background Iron is an essential molecule for cellular physiology, but in excess it facilitates oxidative stress. Mitochondria are
the key regulators of iron homeostasis through heme and iron-sulfur cluster synthesis. Because mitochondrial
function is depressed in failing hearts and iron accumulation can lead to oxidative stress, we hypothesized that
iron regulation may also be impaired in heart failure (HF).
Methods We measured mitochondrial and cytosolic heme and non-heme iron levels in failing human hearts retrieved dur-
ing cardiac transplantation surgery. In addition, we examined the expression of genes regulating cellular iron
homeostasis, the heme biosynthetic pathway, and micro-RNAs that may potentially target iron regulatory net-
works.
Results Although cytosolic non-heme iron levels were reduced in HF, mitochondrial iron content was maintained. More-
over, we observed a significant increase in heme levels in failing hearts, with corresponding feedback inhibition
of the heme synthetic enzymes and no change in heme degradation. The rate-limiting enzyme in heme synthe-
sis, delta-aminolevulinic acid synthase 2 (ALAS2), was significantly upregulated in HF. Overexpression of ALAS2
in H9c2 cardiac myoblasts resulted in increased heme levels, and hypoxia and erythropoietin treatment in-
creased heme production through upregulation of ALAS2. Finally, increased heme levels in cardiac myoblasts
were associated with excess production of reactive oxygen species and cell death, suggesting a maladaptive role
for increased heme in HF.
Conclusions Despite global mitochondrial dysfunction, heme levels are maintained above baseline in human failing hearts.
(J Am Coll Cardiol 2013;61:1884–93) © 2013 by the American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2013.02.012E
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rHeart failure (HF) rates have soared over the last decade,
with almost 6 million Americans affected; the prevalence of
the disease is rising steadily (1). Molecular mechanisms of
HF are complex (2), but mitochondrial dysfunction is an
early and common finding in hypertrophied and failing
hearts (3). Virtually all aspects of mitochondrial physiology
are deranged in HF (4), including mitochondrial number
and biogenesis (5), energetic capacity (6), and production of
reactive oxygen species (ROS) (7). In addition to generating
adenosine triphosphate (ATP), mitochondria play a major
role in the regulation of iron balance and synthesis of heme
and iron-sulfur (Fe/S) clusters (8,9); however, these pro-
cesses have not been systematically examined in failing
hearts.
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2013, accepted February 5, 2013.Indirect evidence points to a link between cellular and
mitochondrial iron regulation and HF. Iron is an essential
molecule that functions as a cofactor in mitochondrial
cytochromes, antioxidant enzymes, and more, and its defi-
ciency is associated with cardiomyopathy (10). In contrast,
the redox properties of iron make it an ideal catalyst for the
production of a toxic hydroxyl radical (OH · ) by the Fenton
reaction (11), and cardiac dysfunction is a prominent feature
of iron overload diseases, such as hemochromatosis (12).
levated iron levels were noted in the hearts of mice
verexpressing the alpha subunit of the Gq protein, a model
f cardiomyopathy (13); however, cellular distribution of
ron has not been assessed. Recently, we have shown that
ccumulation of iron, specifically in the mitochondria
hrough a reduction in the levels of ATP-binding cassette
ransporter B8 (a protein involved in mitochondrial iron
xport), leads to the development of cardiomyopathy in
ice (14). Similarly, aggregation of iron inside the mito-
hondria has been observed in the hearts of Friedreich’s
taxia patients (15), who develop progressive and lethal
ardiac dysfunction (16). Thus, maintenance of iron balance
nside the heart appears to be critical for its function, but it
emains unknown how iron regulation is altered in failing
uman hearts.
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May 7, 2013:1884–93 Heme and Heart FailureIron enters the mitochondria through an inner membrane
transporter mitoferrin 2 (Mfrn2) (17,18), and can either be
stored in a complex with mitoferritin (FtMt) or used in
heme and Fe/S cluster biosynthetic pathways (19). Heme
production begins in the mitochondria with condensation of
glycine and succinyl coenzyme A to form delta-
aminolevulinic acid (ALA) by the rate-limiting enzyme
ALA synthase (ALAS) (9). The next 5 conversions are
carried out in the cytosol. Finally, the synthesis is completed
in the mitochondria with insertion of an iron atom into
protoporphyrin IX (PPIX) to form heme by ferrochelatase
(9) (Fig. 1). In the heart, heme functions as a catalytic or
structural subunit of mitochondrial electron transport chain
(ETC) complexes, myoglobin, antioxidant enzymes, and
components of the cytochrome p450 (20). Moreover, heme
can be broken down by heme oxygenases (HMOX) into
elemental iron, carbon monoxide, and cardioprotective an-
tioxidant biliverdin (21). Despite the essential role heme
plays in the heart, this molecule remains understudied
outside of the erythropoietic system.
Fe/S cluster assembly requires over 20 enzymes and
scaffolding proteins, and takes place primarily in the mito-
chondria (8). Fe/S clusters are incorporated into mitochon-
drial, cytoplasmic, and nuclear proteins involved in oxidative
phosphorylation, DNA repair, purine metabolism, and
heme production (22,23). Disruption of Fe/S cluster syn-
thesis may also lead to cardiomyopathy, as noted in patients
with Friedreich’s ataxia (24) and mice with deletion of
ABCB8 (14), although these conditions are also associated
with mitochondrial iron accumulation and ROS.
Given the critical role mitochondria play both in iron
homeostasis and in HF, we aimed to characterize the
changes in cytosolic and mitochondrial heme and non-heme
iron regulation in human failing hearts. Our results dem-
onstrate that both cytosolic and mitochondrial heme levels
are increased in failing hearts, with feedback inhibition of
the heme synthetic enzymes, except for ALAS2, which is
increased in HF, and whose expression was previously
reported to be restricted to the hematopoietic system. We
also show that in H9c2 cardiac myoblasts, ALAS2 expres-
sion and heme levels are regulated by hypoxia and erythro-
poietin (EPO), the 2 pathways that are often altered in
failing hearts. Furthermore, we demonstrate that increased
heme levels are associated with elevated oxidative stress and
loss of viability in cultured cardiomyoblasts.
Methods
Human samples. Tissue samples were obtained from the
tissue bank at Feinberg Cardiovascular Research Institute
(Northwestern University, Chicago, Illinois) and consisted
of samples from nonfailing (n  10) and failing ischemic
(n  10) human hearts. Failing ischemic tissues were
obtained from the explanted hearts of cardiac transplanta-
tion recipients. Nonfailing heart tissue samples were ob-tained from unmatched organ do-
nors whose hearts were unsuitable
for transplantation, but who had
no known cardiac disease. Ex-
planted hearts were immediately
placed in cold cardioplegic solu-
tion and subsequently frozen in
liquid nitrogen. Protocols for tis-
sue procurement were approved by
the Institutional Review Board of
Northwestern University. In-
formed consent was obtained from
all transplantation patients and
from the families of organ donors
before tissue collection.
Cell culture. H9c2 cardiac myo-
blasts were purchased from
ATCC and kept in complete Dul-
becco’s Modified Eagle Medium
(ATCC, Manassas, Virginia) sup-
plemented with 10% fetal bovine
serum (Invitrogen Grand Island,
New York) and 1% penicillin-
streptomycin. For hypoxic experi-
ments, cells were maintained in a
hypoxic chamber at 37°C and 5%
carbon dioxide in the presence of
1% oxygen for up to 8 days. Me-
dium was replaced every 2 days, and cells were collected under
hypoxia before analysis. For pharmacological treatments, cells
were grown to 80% to 90% confluence and incubated with
10-M hemin (Sigma-Aldrich, St. Louis, Missouri) and
.6 mg/ml EPO (Sigma-Aldrich) for 48 h in complete medium.
Figure 1 Schematic Representation of
Cellular Heme Synthesis Pathway
ALA  delta-aminolevulinic acid; ALAS2  ALA synthase 2; CoA  coenzyme
A; CPgenIII  coproporphyrinogen III ; Fe  iron; Mfrn2  mitoferrin 2; PPIX  proto-
porphyrin IX.
Abbreviations
and Acronyms
ALA  delta-aminolevulinic
acid
ALAS2  ALA synthase 2
ATP  adenosine
triphosphate
ETC  electron transport
chain
EPO  erythropoietin
Fe/S  iron-sulfur
HF  heart failure
HMOX1  heme
oxygenase 1
Mfrn2  mitoferrin 2
FtMt  mitochondrial
ferritin
PCR  polymerase chain
reaction
PPIX  protoporphyrin IX
qRT  quantitative
reverse-transcriptase
ROS  reactive oxygen
species
TfR1  transferrin
receptor 1
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Heme and Heart Failure May 7, 2013:1884–93Mitochondrial fractionation. For tissue samples, we used
the Mitochondria Isolation Kit for Tissue (Pierce, Rock-
ford, Illinois) according to the manufacturer’s dounce ho-
mogenization protocol for hard tissue. Homogenized tissue
was treated with reagents in the presence of ethylenedi-
aminetetraacetic acid–free protease inhibitors (Protease Ar-
rest, G-Biosciences, St. Louis, Missouri). To maintain the
integrity of the mitochondria, samples were kept on ice
during the isolation process. Following differential centrif-
ugation at 4°C, the supernatant (cytosolic fraction) was
collected, and the remaining pellet containing the
mitochondria-enriched fraction was dissolved in 1% Triton
X-100 (Sigma-Aldrich) in Tris-buffered saline (Cellgro,
Manassas, Virginia).
Non-heme iron measurement. Mitochondrial and cytoso-
lic non-heme iron was quantified using a commercial Iron
Assay Kit (BioVision, Milpitas, California). Briefly, tissue
lysate was mixed with acidic solution to release protein-
bound iron, followed by a reduction of iron to its ferrous
form and incubation with a Ferene S compound to produce
a colored complex. The absorbance was then measured on
Spectra Max Plus (Molecular Devices, Sunnyvale, Califor-
nia) microplate reader at 593 nm and normalized to the
protein concentration of each sample.
Heme iron measurement. For determination of total
heme levels,5 mg of frozen tissue was homogenized in 1%
Triton-X100 in Tris-buffered saline and centrifuged at
5,000g for 10 min to remove debris. For determination of
mitochondrial and cytosolic heme levels, the mitochondrial
fraction was isolated using the Mitochondrial Isolation Kit
for Tissue (Pierce) according to the manufacturer’s protocol.
Protein concentration of cytosolic or mitochondrial lysate
was quantified by bicinchoninic acid assay (Pierce), and
heme was quantified as described (25). Briefly, equal
amounts of protein were mixed with 2-M oxalic acid and
heated to 95°C for 30 min to release iron from heme and
generate fluorescent PPIX. Samples were then centrifuged
for 10 min at 1,000g at 4°C to remove debris; the fluores-
cence of the supernatant was assessed at 405 nm/600 nm on
a Spectra Max Gemini fluorescence microplate reader and
normalized to the protein concentration of each sample. For
determination of unsaturated PPIX levels, incubation and
heating with oxalic acid steps were omitted. Instead, sam-
ples were diluted in phosphate-buffered saline, followed by
fluorescence measurement and normalization to protein
content.
Knockdown and overexpression of ALAS2. For knock-
down experiments, ALAS2 and control nontargeting
siRNA (Thermo Scientific) were transfected into H9c2 cells
using Dharmafect I reagent (Thermo Scientific, Hanover
Park, Illinois) for 48 h according to the manufacturer’s
protocol. For hypoxia experiments, transfections were re-
peated every 48 h to maintain low levels of ALAS2
expression throughout the study. Knockdown efficiency was
confirmed by quantitative reverse-transcriptase-polymerase
chain reaction (qRT-PCR) and Western blot analyses.ALAS2 overexpression was achieved through lentiviral
transduction. Lentiviral particles coding for ALAS2-GFP
fusion protein or green fluorescent protein-only control
were transduced into H9c2 cells at equal multiplicity of
infection for 48 h, and overexpression was confirmed by
Western blotting.
Quantitative real-time PCR. RNA was isolated with
RNA STAT-60 (TEL-TEST, Inc., Friendswood, Texas),
reverse-transcribed with a Random Hexamer (Applied Bio-
systems, Foster City, California), and amplified on a 7500
Fast Real-Time PCR system with SYBR Green PCR
Master Mix (Applied Biosystems). Primers were designed
using Primer3 (version 0.4.0) software to target sequences
spanning an exon-intron-exon boundary, and their specific-
ity was confirmed by running a dissociation curve. mRNA
levels were calculated by the comparative threshold cycle
method and normalized to the beta-actin gene.
Mito-DNA/genomic DNA. Total DNA was isolated us-
ing the DNeasy Blood & Tissue Kit (Qiagen), and the ratio
of cytochrome c oxidase I to the genomic 18S gene was
determined by quantitative RT-PCR using SYBR Green
PCR Master Mix (Applied Biosystems).
Western blot. Approximately 5 mg of tissue was homog-
enized in radio-immunoprecipitation assay buffer (Thermo
Scientific) in the presence of Protease Arrest protease
inhibitors (G-Biosciences), centrifuged at 5,000g for 15 min
to remove debris and protein concentration of the superna-
tant determined by BCA assay. Fifteen to 30 g of protein
were resolved on sodium dodecyl sulfate polyacrylamide gel
electrophoresis gels and transferred to nitrocellulose mem-
branes (Invitrogen). The membranes were probed with anti-
bodies against ferritin light and heavy chains (Sigma-Aldrich),
HMOX1 (Abcam, Cambridge, Massachusetts), ALAS1/2
(Abcam), ferrochelatase (Proteintech), phosphor-JAK2
(Tyr1007/1008), JAK2 (Millipore, Billerica, Massachu-
setts), NF-E2 (Proteintech), glyceraldehyde-3-phosphate
dehydrogenase (Santa Cruz), and tubulin (Abcam). Horse-
radish peroxidase-conjugated donkey anti-rabbit and don-
key anti-mouse were used as secondary antibodies (Santa
Cruz, Dallas, Texas) and visualized by Pierce SuperSignal
Chemiluminescent Substrates.
Complex IV activity. Complex IV activity was determined
using the Complex IV Human Enzyme Activity Microplate
Assay Kit (Abcam) according to the manufacturer’s proto-
col. Briefly, complex IV was immobilized in the wells of a
96-well plate by immunocapturing, and the specific activity
was determined colorimetrically as oxidation of cyto-
chrome c, the substrate of complex IV, by measuring absor-
bance change at 550 nm for 2 h at 30°C at 5-min intervals.
Mitochondrial ROS quantification. MitoSox Red (Invit-
rogen) was used to assess mitochondrial O2· production
(26). Cells were visualized by microscopy and ROS levels
were quantified by ImageJ software (National Institutes of
Health, Bethesda, Maryland). Four fields per each sample
were obtained and averaged. Nuclei were counterstained with
Hoescht 33342 dye (Invitrogen) and subtracted from the total
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May 7, 2013:1884–93 Heme and Heart FailureMitosox fluorescence to exclude the signal from localization of
dye into the nucleus. An accurate overlay betweenHoescht and
nuclear MitoSox dye was achieved by adjusting microscopy
settings before data collection, with representative single-
channel and overlay images presented in Online Figure 1A. In
addition, total MitoSox fluorescence without nuclear signal
subtraction was quantified by ImageJ.
Cell death analysis. Following ALAS2 overexpression or
hemin treatment, cells were double-labeled with propidium
iodine (Sigma-Aldrich) and Alexa Fluor 350-conjugated
Annexin V (Molecular Probes, Eugene, Oregon), and
analyzed by flow cytometry in a FacsCanto flow cytometer
(BD Bioscience, San Jose, California). The data are pre-
sented as the sum of apoptotic and necrotic cells normalized
to the control.
Micro-RNA experiments. Taqman micro-RNA assays
(Applied Biosystems) were used to quantify miR144, 145,
148a, 148b, and 152 levels according to the manufacturer’s
protocol. Levels of these micro-RNAs in failing hearts were
quantified by qRT-PCR and normalized to the expression
of small RNA U6. To overexpress miR145, we used
Pre-miR miRNA Precursors, and to downregulate miR145,
we used Anti-miR miRNA Inhibitors (Ambion, Carlsbad,
California). Scrambled Pre-miR and anti-scrambled Anti-
miR were used in control experiments, respectively.
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Figure 2 Heme and Non-Heme Iron Regulation in HF
(A) Cytosolic non-heme iron levels in control and failing hearts normalized to the c
(TfR1), an iron importer, and ferroportin 1, an iron exporter, in heart failure (HF) an
failing hearts normalized to mitochondrial protein content (n  10). (D) Cytosolic
tein concentration of cytosolic and mitochondrial fractions, respectively (n  10).
content (n  10). Data are presented as mean  SEM. *p  0.05 versus controlStatistical analysis. Data are expressed as mean  SEM.
Statistical significance was assessed with the unpaired Stu-
dent t test; a p value of 0.05 was considered statistically
ignificant.
esults
eme is increased in failing hearts. Mitochondria are the
rimary site of heme and Fe/S cluster synthesis, and their
unction is severely impaired in HF (Fig. 1). In this study,
e characterized changes in cellular and mitochondrial iron
omeostasis in failing human hearts. We used left ventric-
lar myocardial tissue from 10 patients with terminal HF
ailure obtained during the heart transplantation surgery and
0 nonmyopathic hearts as controls. Consistent with mito-
hondrial dysfunction that is invariably present in HF
27,28), the mitochondrial DNA copy number and the
ctivity of mitochondrial complex IV were reduced in failing
earts compared with the control hearts (Online Figs. 1B
nd 1C), thus providing molecular confirmation of the
athology report.
We next measured the levels of non-heme and heme iron
n these hearts. There was a significant decrease in cytosolic
evels of non-heme iron (Fig. 2A) and a trend toward a
ecrease in the levels of cytosolic iron storage protein ferritin
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Heme and Heart Failure May 7, 2013:1884–93(heavy and light chains) (Online Figs. 2A and 2B). More-
over, mRNA levels of transferrin receptor 1 (TfR1), a
protein facilitating cellular iron import, were greatly re-
duced, whereas the expression of ferroportin 1, an iron
exporter, remained stable (Fig. 2B), suggesting that the
observed deficiency may be due to a reduction in iron import
in cardiomyocytes. However, mitochondrial non-heme iron
content was unaltered in failing hearts (Fig. 2C), suggesting
that the delivery of iron to the mitochondria remains intact
in HF.
Heme levels were significantly increased in the cytosolic
(Fig. 2D) and mitochondrial (Fig. 2E) fractions in failing
hearts, as determined by the increase in fluorescence of the
PPIX ring, the last synthetic intermediate in the heme
synthesis pathway (25). The observed increase was not due
to accumulation of unsaturated PPIX, because the levels of
iron-free PPIX were comparable between the 2 groups
(Online Fig. 2C). Thus, although mitochondrial biogenesis
and energetic function are depressed in HF, mitochondrial
iron levels (Fig. 2F) (obtained by the addition of heme and
non-heme mitochondrial iron contents) and heme content
in this organelle are increased in failing hearts.
ALAS2 expression is induced in HF. To understand the
mechanism of increased heme levels in HF, we assessed the
expression of genes directly involved in the breakdown or
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Figure 3 ALAS2 Is Upregulated in Failing Hearts
(A) mRNA and (B) protein levels of heme oxygenase 1 (HMOX1) in control and fai
ing hearts (n  4 to 6). (E) Western blot analysis of ALAS1/2 proteins in H9c2 wi
sented below the Western blots. (F) Heme levels in H9c2 cells transduced with
*p  0.05 versus control group. GADPH  glyceraldehyde-3-phosphate dehydrsynthesis of heme. The levels of HMOX1 and 2, the
enzymes that catalyze degradation of heme, were not altered
(Figs. 3A and 3B, Online Fig. 3A). These results indicate
that the increase in heme levels in HF is not likely caused by
impaired degradation of heme. Many of the enzymes
involved in heme synthesis, including ferrochelatase respon-
sible for iron insertion in PPIX, were actually downregu-
lated in the failing hearts (Online Figs. 3B and 3C),
suggesting a feedback inhibition on the pathway by high
cellular levels of heme, as has been previously reported (9).
owever, mRNA and protein levels of ALAS2, a rate-
imiting enzyme catalyzing the first committed step in heme
ynthesis (29), were significantly upregulated in the failing
earts (Figs. 3C and 3D), providing a potential mechanism
or heme accumulation in HF.
The upregulation of ALAS2 in HF is surprising, because
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verexpression of human ALAS2 in H9c2 cells resulted in
2-fold increase in its protein levels (Fig. 3E). Consistent
ith our findings in human hearts, heme content was
levated in ALAS2-overexpressing cells (Fig. 3F). More-
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May 7, 2013:1884–93 Heme and Heart Failureover, mRNA and protein levels of ALAS1, the nonerthroid
isoform of the enzyme, were decreased with ALAS2 over-
expression (Fig. 3E, Online Fig. 3D), consistent with the
feedback inhibition by high intracellular heme content (30).
Regulation of ALAS2 in cardiac cells. Mechanisms for
regulation of ALAS2 in hematopoietic cells have been
extensively characterized, but it is unknown how ALAS2 is
regulated in the heart. The major inducer of ALAS2 in
developing erythrocytes is the GATA1 transcription factor.
However, qRT-PCR analysis revealed no expression of
GATA1 in human hearts (qRT-PCR cycle 34.85  0.32).
n contrast, protein levels of NF-E2, an erythroid transcrip-
ion factor that has putative binding sites in the promo-
er of ALAS2 (31), were significantly higher in the HF
roup compared with the control group (Online Figs. 4A
nd 4B).
Because ischemia is common in failing hearts, and
LAS2 was shown to be regulated by hypoxia-inducible
actor 1-alpha in erythroid lineage (32), we assessed regu-
ation of ALAS2 by low oxygen tension by subjecting H9c2
ells to 1% oxygen levels. We found ALAS2 expression to be
ignificantly induced by long-term (8 day), but not acute exposure,
o hypoxia (Figs. 4A and 4B), with a corresponding increase in
ellular heme content at day 8 (Fig. 4C). Treatment of cells with
LAS2 siRNA during hypoxic incubation effectively ablated an
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Figure 4 Regulation of ALAS2 by Hypoxia in Cardiac Myoblasts
(A) Time-course of ALAS2 mRNA expression in H9c2 cardiac myoblasts subjected
6). (C) Cellular heme content after 8 days in hypoxia or normoxia (n  6). (D) mR
without siRNA-mediated ALAS2 knockdown (n  6). (E) Comparison of ALAS2 mRN
6). (F) Heme levels in control normoxic and ALAS2 siRNA hypoxic cells after 8 day
Abbreviations as in Figure 1.ncrease in ALAS2 mRNA levels, bringing it down to the
ormoxic levels (Figs. 4D and 4E), and also prevented the increase
n cellular heme (Fig. 4F). These data suggest that long-standing
schemia of failing hearts may potentially be responsible for the
nduction of ALAS2, and provide further evidence that upregu-
ation of ALAS2 in HFmay mediate the increase in heme levels.
Finally, ALAS2 is known to be positively regulated by
PO in erythroblasts (33), and EPO levels are often
levated in HF patients due to underlying anemia (34). The
PO receptor was previously shown to be expressed in the
uman heart (35), suggesting that cardiomyocytes may
espond to EPO signaling. Western blot analysis of JAK2
inase, the downstream effector of EPO signaling (36),
evealed that elevated phosphorylation of this protein was
onsistent with activation of the EPO receptor (Fig. 5A).
ncubation of H9c2 myoblasts with EPO also significantly
ncreased p-JAK2 levels (Fig. 5B) and was associated with
nduction of the ALAS2 enzyme on mRNA and protein
evels (Figs. 5B and 5C). Heme content was increased in
PO-treated cells (Fig. 5D), whereas suppression of
LAS2 upregulation by EPO using siRNA reversed this
ncrease (Figs. 5E and 5F). Thus, similar to erythropoetic
ells, cardiac ALAS2 is responsive to EPO stimulation,
hich causes an increase in heme levels and may potentially
ontribute to cardiac heme loading in HF, particularly in the
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Heme and Heart Failure May 7, 2013:1884–93setting of underlying anemia. In summary, we found
ALAS2 to be positively regulated by hypoxia and EPO in
cardiac cells.
Heme and oxidative stress. Heart failure is characterized
by increased oxidative stress, which significantly disrupts
myocardial architecture and signaling (37). Free heme has
been suggested to exert toxic effects through oxidation of
phospholipids, mtDNA damage, and activation of the
inflammatory response (38). To determine if excess levels of
heme contribute to oxidative stress in cardiac myoblasts, we
incubated H9c2 cells with hemin and measured mitochon-
drial ROS production and cell death using MitoSox and
propidium iodine staining, respectively. Addition of he-
min led to a significant increase in ROS levels (Figs. 6A
and 6B, Online Fig. 4C) and was associated with the loss
of cell viability (Fig. 6C). Overexpression of ALAS2 in
H9c2 also induced an increase in ROS (Figs. 6D and 6E,
Online Fig. 4D) and was associated with increased cell
death (Fig. 6F). These data suggest that elevated heme
production in HF may be maladaptive through enhancing
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May 7, 2013:1884–93 Heme and Heart FailureALA, the rate-limiting intermediate in the heme synthe-
sis pathway, and observed a significant increase in heme
levels (Online Fig. 5H), but no change in miR145
expression (Online Fig. 5I). Taken together, these results
showed that although miR-145 is significantly upregu-
lated in the failing hearts, it does not mediate changes in
heme and non-heme iron homeostasis observed in HF
and is not regulated by cellular heme levels.
Discussion
The goal of this study was to characterize changes in iron
homeostasis occurring in failing human hearts. Despite
mitochondrial dysfunction, which is characteristic of HF,
the mitochondria-dependent process of heme synthesis was
significantly upregulated in failing hearts. We also observed
induction of ALAS2, a rate-limiting enzyme in heme
synthesis that was previously reported to be expressed
exclusively in hematopoietic cells. Moreover, mitochondrial
iron levels were maintained at normal levels and were
sufficient to support heme synthesis, because we detected
very low levels of unsaturated PPIX in the HF group.
It is presently unclear whether the increase in heme levels
in HF is an adaptive or maladaptive process. Heme degra-
dation by HMOX1 confers cardiac protection through
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However, free heme is toxic to the cell because it catalyzes
oxidation and breakdown of proteins and DNA, intercalates
into lipid bilayers, and damages membrane-bound organ-
elles (38). Similarly, we found that treatment of cardiac
myoblasts with hemin significantly elevated ROS genera-
tion in the mitochondria and led to a loss in cell viability.
Similarly, overexpression of ALAS2, which increases heme
content in H9c2 cells, increased both ROS and cell death.
In contrast, the levels of HMOX1 were unaltered in the HF
samples we examined, suggesting that HMOX1-dependent
antioxidation is unlikely to protect hearts from heme toxic-
ity. Based on the in vitro data, we speculated that the
induction of heme synthesis in these hearts might be
maladaptive through an increase in oxidative stress. Al-
though our data suggested that iron supplementation and
stimulants of EPO in anemic HF patients, which yielded
controversial results (43), might negatively affect cardio-
myocytes through induction of ALAS2 and heme syn-
thesis, potential benefits of iron supplementation, as
previously demonstrated (44), on other organs and the
hematopoietic system could not be excluded. It is impor-
tant to note, however, that our data only provided an
association among induction of ALAS2, elevated cardiac
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of this hypothesis directly.
Although our experimental design does not identify the
mechanism for increased heme synthesis and ALAS2 in-
duction, we hypothesize that chronic ischemia and EPO
may play a role. Two isoforms of ALAS enzyme have been
identified. ALAS1 is a ubiquitously expressed housekeeping
gene and is negatively regulated by heme (45,46). In
contrast, ALAS2 expression is traditionally studied in the
context of erythrocyte maturation, where it is induced to
stimulate hemoglobinization (47,48). Unlike other compo-
nents of the heme synthesis pathway, including ALAS1,
ALAS2 is not inhibited by high levels of heme and is
positively regulated by hypoxia (32,49). Our studies show
that ALAS2 is expressed in the heart and is significantly
upregulated in HF, providing the first evidence of a heart-
specific function for this “noncardiac” isoform of ALAS.
We confirm that, similar to erythroid cells, ALAS2 is
regulated by hypoxia in cardiac myoblasts, and that the
increase in heme observed in cells subjected to long-term
hypoxia is mediated by ALAS2 induction, because knock-
down of this protein has also abolished an increase in heme.
Moreover, we find that, similar to developing erythrocytes,
EPO stimulation induces ALAS2 expression and subse-
quently elevates heme levels. The significance of these
findings in the context of failing hearts remains to be
determined. Despite elevated EPO levels, HF patients were
found to be resistant to EPO signaling in promoting
hematopoiesis (34), but it remains unknown whether the
sensitivity of cardiomyocytes to EPO stimulation is also
altered.
In addition to showing an increase in heme content in
HF, we find that miR-145 is strongly induced in failing
human hearts, but it does not mediate the changes in heme
observed in HF. MiR-145 is known to play a role in smooth
muscle differentiation (50,51) and also exhibits tumor sup-
pressor activity (52,53). To the best of our knowledge, this
is the first report of miR145 upregulation in HF, and
naturally, it will be of interest to see if this induction has any
functional consequences.
We show that mitochondrial iron levels are increased in
failing hearts due to an increase in heme content, suggesting
that mitochondrial iron homeostasis is maintained despite
severe mitochondrial dysfunction. We would like to note,
however, that preservation of mitochondrial iron content
does not necessarily imply that all iron-dependent processes
remain unaffected. Specifically, it remains to be determined
how HF affects the process of Fe/S cluster assembly in the
mitochondria and their incorporation into proteins. Fe/S
clusters are essential for maintenance of normal energy
homeostasis, because they are required for the function of
several subunits of ETC complexes and the tricarboxylic
cycle enzyme aconitase. We and others report reduced
activity of ETC complexes and aconitase in HF, suggesting
that Fe/S cluster biosynthesis may be disrupted in failing
hearts (54).Study limitations. The potential limitations of our studies
include the lack of data on demographics, the underlying
cause of HF, and/or medical therapy received by patients
before the transplantation surgery and retrieval of the heart.
Likely, our samples come from a heterogeneous patient
population. The effects of medications, methods for preser-
vation, and ischemic time for both control and failing hearts
are important factors that may have affected the reported
findings. Finally, the mechanisms of cellular iron regulation
are complex and multiple. Thus, unmeasured confounders
may potentially contribute to the presented findings.
Conclusions
In this study we report increased myocardial heme levels in
human failing hearts. While the exact mechanism and
pathologic significance of this finding requires further in-
vestigation, hypoxia- or erythropoietin-driven upregulation
of ALAS2 may play a role. In summary, our data suggest
that induction heme synthesis pathway represents a com-
mon and important pathophysiologic finding in HF.
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